Nothing Special   »   [go: up one dir, main page]

EA202090486A2 - Соединения для лечения спинальной мышечной атрофии - Google Patents

Соединения для лечения спинальной мышечной атрофии

Info

Publication number
EA202090486A2
EA202090486A2 EA202090486A EA202090486A EA202090486A2 EA 202090486 A2 EA202090486 A2 EA 202090486A2 EA 202090486 A EA202090486 A EA 202090486A EA 202090486 A EA202090486 A EA 202090486A EA 202090486 A2 EA202090486 A2 EA 202090486A2
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
treatment
muscular atrophy
spinal muscular
formula
Prior art date
Application number
EA202090486A
Other languages
English (en)
Other versions
EA202090486A3 (ru
Inventor
Хасан Ратни
Люк Грин
Николай А. Нарышкин
Марла Л. Витолл
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Птс Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202090486(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг, Птс Терапьютикс Инк. filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA202090486A2 publication Critical patent/EA202090486A2/ru
Publication of EA202090486A3 publication Critical patent/EA202090486A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены соединения формулы (I)где A, R, Rи Rявляются такими, как здесь описано, а также их фармацевтически приемлемые соли. Также настоящее изобретение относится к получению соединений формулы (I), содержащим их фармацевтическим композициям и их применению в качестве лекарственных средств.
EA202090486A 2014-05-15 2015-05-11 Соединения для лечения спинальной мышечной атрофии EA202090486A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15

Publications (2)

Publication Number Publication Date
EA202090486A2 true EA202090486A2 (ru) 2020-06-30
EA202090486A3 EA202090486A3 (ru) 2020-08-31

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201692280A EA035068B1 (ru) 2014-05-15 2015-05-11 Соединения для лечения спинальной мышечной атрофии
EA202090486A EA202090486A3 (ru) 2014-05-15 2015-05-11 Соединения для лечения спинальной мышечной атрофии

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201692280A EA035068B1 (ru) 2014-05-15 2015-05-11 Соединения для лечения спинальной мышечной атрофии

Country Status (36)

Country Link
US (1) US9969754B2 (ru)
EP (3) EP3663296B1 (ru)
JP (1) JP6236173B2 (ru)
KR (2) KR102256013B1 (ru)
CN (1) CN106459092B (ru)
AR (1) AR100442A1 (ru)
AU (1) AU2015261046C1 (ru)
BR (1) BR112016026205B1 (ru)
CA (1) CA2948561C (ru)
CL (1) CL2016002836A1 (ru)
CR (1) CR20160518A (ru)
DK (1) DK3143025T3 (ru)
EA (2) EA035068B1 (ru)
ES (2) ES2949660T3 (ru)
FR (1) FR21C1039I2 (ru)
HR (2) HRP20230637T1 (ru)
HU (2) HUE046491T2 (ru)
IL (2) IL248653B (ru)
LT (1) LTPA2021010I1 (ru)
MA (2) MA39995B1 (ru)
MX (1) MX371050B (ru)
MY (1) MY174284A (ru)
NL (1) NL301128I2 (ru)
NO (1) NO2021035I1 (ru)
NZ (1) NZ725008A (ru)
PE (1) PE20170128A1 (ru)
PH (1) PH12016502081A1 (ru)
PL (2) PL3143025T3 (ru)
PT (1) PT3143025T (ru)
RS (1) RS59718B1 (ru)
SG (1) SG11201609497TA (ru)
SI (2) SI3663296T1 (ru)
TW (1) TWI667239B (ru)
UA (1) UA119670C2 (ru)
WO (1) WO2015173181A1 (ru)
ZA (1) ZA201607026B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
WO2015024876A2 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
WO2016184832A1 (en) 2015-05-20 2016-11-24 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
JP6659841B2 (ja) * 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物
MX2018005041A (es) * 2015-11-12 2018-08-01 Hoffmann La Roche Compuestos para tratar la esclerosis lateral amiotrofica.
MX2021001091A (es) 2015-12-10 2022-04-26 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
JP6872550B2 (ja) 2015-12-10 2021-05-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 架橋されたピペリジン誘導体
CN110352007A (zh) * 2016-11-28 2019-10-18 Ptc医疗公司 用于调节rna剪接的方法
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
CA3065547A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020005549A2 (pt) * 2017-09-22 2020-10-06 F. Hoffmann-La Roche Ag processo para a preparação de derivados de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona
KR20200065025A (ko) * 2017-10-03 2020-06-08 에프. 호프만-라 로슈 아게 척수성 근위축증의 새로운 치료법
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
MX2020014116A (es) 2018-06-27 2021-06-15 Reborna Biosciences Inc Agente profilactico o terapeutico para atrofia muscular espinal.
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
TW202035411A (zh) 2018-10-19 2020-10-01 瑞士商赫孚孟拉羅股份公司 吡啶并[1,2-a]嘧啶-4-酮衍生物之新型式、及調配物及製備方法
EP3982970A1 (en) 2019-06-12 2022-04-20 F. Hoffmann-La Roche AG New treatment of sma
WO2021021775A1 (en) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
BR112023018466A2 (pt) 2021-03-17 2023-10-10 Hoffmann La Roche Derivados de tiazolopirimidinona
JP2024510487A (ja) * 2021-03-17 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 新規なチアジアゾロピリミドン誘導体
CN117015546A (zh) 2021-03-18 2023-11-07 豪夫迈·罗氏有限公司 制备利司扑兰的方法
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
US20240173325A1 (en) 2022-10-14 2024-05-30 Genentech, Inc. Methods for treating spinal muscular atrophy
WO2024154148A1 (en) * 2023-01-21 2024-07-25 Harman Finochem Limited Process for preparation of risdiplam, novel intermediates, and process for preparation thereof
WO2024218207A1 (en) 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Thieno[3,2-b]pyridine derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000029843A (ko) * 1996-08-06 2000-05-25 디. 제이. 우드;스피겔 알렌 제이 치환된피리도-또는피리미도-함유6,6-또는6,7-비시클릭유도체
AU2008304231A1 (en) 2007-09-27 2009-04-02 Albany Molecular Research, Inc. Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) 2008-07-28 2010-02-08 신호열 마우스
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
JP2011529722A (ja) * 2008-08-14 2011-12-15 カーディアック ペースメイカーズ， インコーポレイテッド 音響通信リンクの性能評価および適合
JP6193881B2 (ja) * 2011-12-30 2017-09-06 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
AU2013289938A1 (en) 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
JP6659841B2 (ja) 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物

Also Published As

Publication number Publication date
EP3143025A1 (en) 2017-03-22
SG11201609497TA (en) 2016-12-29
IL248653B (en) 2019-11-28
ES2949660T3 (es) 2023-10-02
MA39995B1 (fr) 2019-11-29
RS59718B1 (sr) 2020-01-31
PL3143025T3 (pl) 2020-03-31
HRP20192159T1 (hr) 2020-02-21
UA119670C2 (uk) 2019-07-25
CN106459092B (zh) 2019-10-15
AR100442A1 (es) 2016-10-05
MX2016014547A (es) 2017-02-23
IL248653A0 (en) 2017-01-31
WO2015173181A1 (en) 2015-11-19
FR21C1039I2 (fr) 2022-09-02
FR21C1039I1 (ru) 2021-10-15
EP3663296A1 (en) 2020-06-10
BR112016026205B1 (pt) 2021-12-07
EA035068B1 (ru) 2020-04-23
PH12016502081A1 (en) 2017-01-09
HUE046491T2 (hu) 2020-03-30
KR20170003687A (ko) 2017-01-09
LTPA2021010I1 (ru) 2021-10-11
TW201609738A (zh) 2016-03-16
DK3143025T3 (da) 2019-12-09
MA51988A (fr) 2021-01-20
PE20170128A1 (es) 2017-03-16
MY174284A (en) 2020-04-01
EP4241772A2 (en) 2023-09-13
SI3663296T1 (sl) 2023-08-31
NL301128I1 (ru) 2021-09-22
JP2017515863A (ja) 2017-06-15
ZA201607026B (en) 2022-05-25
CA2948561C (en) 2019-10-22
IL270027B (en) 2020-08-31
CR20160518A (es) 2017-02-21
KR20210014219A (ko) 2021-02-08
BR112016026205A2 (pt) 2017-08-15
PL3663296T3 (pl) 2023-08-07
MX371050B (es) 2020-01-14
JP6236173B2 (ja) 2017-11-22
AU2015261046C1 (en) 2019-07-25
TWI667239B (zh) 2019-08-01
PT3143025T (pt) 2019-12-03
HRP20230637T1 (hr) 2023-09-29
US20170197990A1 (en) 2017-07-13
EP3663296B1 (en) 2023-05-17
CA2948561A1 (en) 2015-11-19
BR112016026205A8 (pt) 2021-07-20
HUS2100037I1 (hu) 2021-10-28
EA202090486A3 (ru) 2020-08-31
NZ725008A (en) 2019-11-29
ES2761423T3 (es) 2020-05-19
AU2015261046A1 (en) 2016-10-27
AU2015261046B2 (en) 2019-04-18
US9969754B2 (en) 2018-05-15
CL2016002836A1 (es) 2017-04-21
SI3143025T1 (sl) 2020-01-31
EA201692280A1 (ru) 2018-07-31
CN106459092A (zh) 2017-02-22
NO2021035I1 (no) 2021-09-10
EP4241772A3 (en) 2023-11-15
KR102213740B1 (ko) 2021-02-09
KR102256013B1 (ko) 2021-05-26
EP3143025B1 (en) 2019-10-09
NL301128I2 (nl) 2021-10-25

Similar Documents

Publication Publication Date Title
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
PH12018500065A1 (en) Oxysterols and methods of use thereof
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
PH12018500061A1 (en) Oxysterols and methods of use thereof
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
NZ746825A (en) Oxysterols and methods of use thereof
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201692003A1 (ru) Макроциклические производные пиримидина
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
EA201790570A1 (ru) Модуляторы р2х7
EA201890532A1 (ru) Новые аннелированные бензамиды
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201600434A1 (ru) Применение производных бензимидазолпролина